ESC Premium Access

Discussion - How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation.

Topic: Inflammation and microcirculation
Organised by Academic Medical Center Amsterdam. Dept Vascular Medicine and Physicians' Academy for Cardiovascular Education / Course Director: Prof John Kastelein / Supported by unrestricted educational grants from Novartis and Amgen

Congress Presentation

About the speakers

Professor Peter Libby

Brigham and Women's Hospital, Boston (United States of America)
35 presentations
6 followers

Professor John Eric Deanfield

University College London, London (United Kingdom of Great Britain & Northern Ireland)
50 presentations
3 followers

4 more presentations in this session

Introduction - The post ACS patient and residual risk.

Speaker: Professor P. Libby (Boston, US)

Thumbnail

Inflammation as potential target for therapy to target residual risk post ACS.

Speaker: Doctor P. Ridker (Boston, US)

Thumbnail

Beyond statins: the role of ezetimibe in targeting residual risk.

Speaker: Professor C. Packard (Glasgow, GB)

Thumbnail

Novel strategies targeting residual risk: the promise of PCSK9 inhibiting therapies.

Speaker: Professor E. Stroes (Amsterdam, NL)

Thumbnail

Access the full session

How to address residual risk post ACS: LDL-c, dyslipidemia, and inflammation

Speakers: Professor P. Libby, Professor J. Deanfield, Professor P. Libby, Doctor P. Ridker, Professor C. Packard...
Thumbnail

About the event

Image

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb